CD44 and neoplasm: Recent work by Mahoutforoush et al. (2025) demonstrated that UiO-66 metal–organic frameworks functionalized with dermatan sulfate (a sulfated polysaccharide) enable dual active/passive targeting of cancer cells, combining receptor-mediated uptake (via CD44) with pH-responsive drug release in the acidic tumor microenvironment25.